Skip to main content

Monopar Therapeutics

MNPR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001645469

In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 3 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in Monopar Therapeutics as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
13
No complete 13F data for Q4 2020
Shares held
194.8K
No complete 13F data for Q4 2020
Total value
$1.21M
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting MNPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 13 institutions
Q1 2021: 13 institutionsQ2 2021: 10 institutionsQ3 2021: 9 institutionsQ4 2021: 13 institutionsQ1 2022: 13 institutionsQ2 2022: 13 institutionsQ3 2022: 10 institutionsQ4 2022: 10 institutionsQ1 2023: 11 institutionsQ2 2023: 8 institutionsQ3 2023: 14 institutionsQ4 2023: 14 institutionsQ1 2024: 16 institutionsQ2 2024: 12 institutionsQ3 2024: 6 institutionsQ4 2024: 18 institutionsQ1 2025: 35 institutionsQ2 2025: 43 institutionsQ3 2025: 56 institutionsQ4 2025: 74 institutionsQ1 2026: 82 institutionsQ2 2026: 95 institutions
Value heldQ1 2021: $1.21M
Q1 2021: $1.21MQ2 2021: $1.10MQ3 2021: $964.4KQ4 2021: $657.2KQ1 2022: $519.8KQ2 2022: $470.6KQ3 2022: $314.0KQ4 2022: $471.0KQ1 2023: $322.9KQ2 2023: $164.5KQ3 2023: $182.2KQ4 2023: $91.7KQ1 2024: $268.1KQ2 2024: $310.1KQ3 2024: $105.9KQ4 2024: $57.1MQ1 2025: $109.4MQ2 2025: $113.3MQ3 2025: $354.3MQ4 2025: $360.8MQ1 2026: $341.5MQ2 2026: $576.1M
Institutions holding MNPR and their total value by quarter
QuarterHoldersValue
Q2 202695$576.1M
Q1 202682$341.5M
Q4 202574$360.8M
Q3 202556$354.3M
Q2 202543$113.3M
Q1 202535$109.4M
Q4 202418$57.1M
Q3 20246$105.9K
Q2 202412$310.1K
Q1 202416$268.1K
Q4 202314$91.7K
Q3 202314$182.2K
Q2 20238$164.5K
Q1 202311$322.9K
Q4 202210$471.0K
Q3 202210$314.0K
Q2 202213$470.6K
Q1 202213$519.8K
Q4 202113$657.2K
Q3 20219$964.4K
Q2 202110$1.10M
Q1 202113$1.21M

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Monopar Therapeutics.

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding MNPR in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Marshall Wace, LLP47,653$295.0K0.00%––
Vanguard Group Inc45,070$279.0K0.00%––
Northern Trust Corp36,001$223.0K0.00%––
Geode Capital Management, LLC26,394$163.0K0.00%––
Citadel Advisors LLC12,479$77.0K0.00%––
BlackRock Inc.11,229$70.0K0.00%––
Royal Bank of Canada9,130$57.0K0.00%––
Morgan Stanley3,200$20.0K0.00%––
Tower Research Capital LLC (TRC)2,212$14.0K0.00%––
American Portfolios Advisors700$4.34K0.00%––
UBS Group AG571$4.00K0.00%––
Captrust Financial Advisors170$1.00K0.00%––
Wells Fargo & Company19$00.00%––